3rd Quarter - Report — ASTRAZENECA PHARMACEUTICALS LP for ASTRAZENECA PHARMACEUTICALS LP (2013)

Firm

ASTRAZENECA PHARMACEUTICALS LP

Client

ASTRAZENECA PHARMACEUTICALS LP

Income

—

Expenses

$970,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Intellectual property, regulatory harmonization and transparency in free trade agreements

Lobbyist	Covered position, as disclosed
BRADLEY ALLEN ROSSIN	—

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Health Resources & Services Administration (HRSA); U.S. Trade Representative (USTR); Commerce, Dept of (DOC)

Taxation/Internal Revenue Code TAX

Reform of tax code and possible timing of any such reform bill (no bill number yet)

Lobbyist	Covered position, as disclosed
BRADLEY ALLEN ROSSIN	—

Contacted: U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); Health Resources & Services Administration (HRSA); SENATE

Copyright/Patent/Trademark CPT

H.R. 2582 - Patent user fees H.R. 2766 - patent reform H.R. 3116 - MODDERN Cures Act - legislation to provide patent incentives for the development of innovative diagnostic tests therapies

Lobbyist	Covered position, as disclosed
CARRIE HARNEY	—
THERESA JOLIVETTE	—
JACQUELINE POMFRET KIRBY	—
HEATHER STRAWN	—

Contacted: Health Resources & Services Administration (HRSA); Commerce, Dept of (DOC); SENATE; U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES

Bills named: H.R. 3116 (113th), H.R. 2766 (113th), H.R. 2582 (113th)

Oversight and possible amendment or reform of federal 340B pharmaceutical purchasing program H.R. 1919, H.R. 3204, S.959, S.957 and related legislative proposals - Drug safety and supply chain protections Legislative proposals regarding the development of antibiotics (no assigned legislation) H.R. 2725, S. 1413 - FDA user feesH.R. 3116 - MODDERN Cures Act - legislation to provide patent incentives for the development of innovative diagnostic tests therapies Federal revenues, entitlement reform, and deficit reduction regarding ongoing fiscal talks and sequestration HR 2985 - regarding the development of new combination drugs

Lobbyist	Covered position, as disclosed
CARRIE HARNEY	—
THERESA JOLIVETTE	—
JACQUELINE POMFRET KIRBY	—
BELA SASTRY	—
HEATHER STRAWN	—

Contacted: Commerce, Dept of (DOC); U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; Health Resources & Services Administration (HRSA); SENATE

Bills named: H.R. 3204 (113th), H.R. 1919 (113th), H.R. 2725 (113th), S. 959 (113th), H.R. 2985 (113th), S. 1413 (113th), S. 957 (113th)

Medicare/Medicaid MMM

H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - Medicare and Medicaid reform including issues related to adherence programs H.R. 1588, S. 740 - issues related to pharmaceutical rebates in Medicare Part D

Lobbyist	Covered position, as disclosed
THERESA JOLIVETTE	—
JACQUELINE POMFRET KIRBY	—
BELA SASTRY	—
HEATHER STRAWN	—

Contacted: Health Resources & Services Administration (HRSA); SENATE; U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC)

Bills named: H.R. 1588 (113th), S. 740 (113th), H.R. 3590 (113th)

Consumer Issues/Safety/Products CSP

H.R. 1919, H.R. 3204, S.959, S.957 and related legislative proposals - Drug safety and supply chain protections

Lobbyist	Covered position, as disclosed
CARRIE HARNEY	—
THERESA JOLIVETTE	—
JACQUELINE POMFRET KIRBY	—
BELA SASTRY	—
HEATHER STRAWN	—

Contacted: SENATE; U.S. Trade Representative (USTR); Health Resources & Services Administration (HRSA); HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC)

Bills named: S. 957 (113th), H.R. 3204 (113th), H.R. 1919 (113th), S. 959 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.